Osteoporosis dan Terapi Bisfosfonat
DOI:
https://doi.org/10.55175/cdk.v45i7.752Kata Kunci:
Bifosfonat, bone mineral density, fraktur, osteoporosisAbstrak
Osteoporosis sering ditemukan dalam praktik sehari-hari di Indonesia. Osteoporosis memiliki karakteristik berupa penurunan densitas mineral tulang/bone mineral density (BMD). Faktor risiko osteoporosis antara lain keturunan, diet rendah kalsium, merokok, konsumsi berlebihan alkohol dan kafein, penggunaan steroid jangka panjang, dan latihan fisik inadekuat. Untuk kelompok berisiko tinggi, disarankan pemeriksaan DXA untuk skrining dan diagnosis osteoporosis. Komplikasi osteoporosis antara lain fraktur vertebra, non-vertebra, dan pinggul. Salah satu terapi osteoporosis adalah bisfosfonat, khususnya yang mengandung nitrogen (alendronate, risedronate, ibandronate, zolendronate).
Osteoporosis is a common problem found in daily practice in Indonesia. Osteoporosis is characterized by the decline in bone mineral density (BMD). Risk factors of osteoporosis are family history of osteoporosis, low calcium diet, smoking, overconsumption of alcohol and caffeine, long term steroid usage, and inadequate physical activity. DXA examination for screening and diagnosis is suggested for high risk group. The complications of osteoporosis are vertebral, non-vertebral, and hip fractures. On of osteoporosis therapy is bisphosphonate, especially nitrogen containing bisphosphonates (alendronate, risedronate, ibandronate, zolendronate).
Unduhan
Referensi
Salter RB. Textbook of disorders and injuries of the musculoskeletal system. Maryland: Lippincott Williams & Wilkins; 1999. p.190-4.
International Osteoporosis Foundation. Indonesia [Internet]. 2013 [cited 2017 Oct 25]. Available from: https://www.iofbonehealth.org/sites/default/files/PDFs/Audit%20Asia/Asian_regional_audit_Indonesia.pdf.
Pusat Data dan Informasi Kementerian Kesehatan RI. Data & kondisi penyakit osteoporosis di Indonesia. Jakarta; 2015.
Solomon S, Warwick D, Nagayam S. Apley’s system of orthopaedics and fracture. 5th ed. London: Hodder Arnold; 2010. p. 131-5.
Bethel M, Carbone LD, Lohr KM, Machua W. Osteoporosis. Medscape [Internet]. 2017 [cited 2017 Oct 31]. Available from: https://emedicine.medscape.com/article/330598-overview.
Kling JM, Clarke BL, Sandhu NP. Osteoporosis prevention, screening, and treatment: A review. J Womens Health. 2014;23(7):563-72. doi: 10.1089/jwh.2013.4611
Lewiecki EM. Bisphosphonates for the treatment of osteoporosis: insights for clinicians. Ther Adv Chronic Dis. 2010;1(3):115-28. doi: 10.1177/2040622310374783
Kennel KA, Drake MT. Adverse effects of bisphosphonates: Implications for osteoporosis management. Mayo Clin Proc. 2009;84(7):632-8. doi: 10.1016/S0025-6196(11)60752-0
International Osteoporosis Foundation. Bisphosphonates [Internet]. [cited 2017 Oct 25]. Available from: https://www.iofbonehealth.org/bisphosphonates.
Miller PD. Long-term extension trials to prove the efficacy and safety of bisphosphonates. Clin Invest. 2014;4(1):35-43.
Budlovsky J, Dian L. Questions in osteoporosis management. BCMJ. 2017;59(2):106-11.
Whitaker M, Guo J, Kehoe T, Benson G. Bisphosphonates for osteoporosis-where do we go from here? N Engl J Med. 2012;366:2048-51. doi:10.1056/NEJMp1202619
Black DM, Bauer DC, Schwartz AV, Cummings SR, Rosen CJ. Continuing bisphosphonate treatment for osteoporosis-for whom and how long? N Engl J Med. 2012;366:2051-3. doi:10.1056/NEJMp1202623.
Adler RA, El-Hajj Fuleihan G, Bauer DC, Camacho PM, Clarke BL, Clines GA, et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2016;31(1):16-35. doi: 10.1002/jbmr.2708.
Todd N. Slideshow: A visual guide to osteoporosis [Internet]. [cited 2017 Oct 31]. Available from: https://www.webmd.com/osteoporosis/ss/slideshow-osteoporosisoverview.
Singapore Sports & Orthopaedic Surgeon. Bone mineral density (BMD) [Internet]. [cited 2017 Oct 31]. Available from: https://www.orthopaedicsurgeon.com.sg/radiology-services/bone-mineral-densitometry-bmd/
Unduhan
Diterbitkan
Cara Mengutip
Terbitan
Bagian
Lisensi
Hak Cipta (c) 2018 https://creativecommons.org/licenses/by-nc/4.0/
Artikel ini berlisensi Creative Commons Attribution-NonCommercial 4.0 International License.